Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 5/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.39 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.39 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28745441 | 1.00 | TACR2 (0.42) | TACR2SIGMAR1ADRA1DADRA1ACTSL | |
| SCHEMBL6895021 | 0.94 | ALDH1A1 (0.42) | TACR2SIGMAR1ADRA1DADRA1ACTSL | |
| SCHEMBL6889070 | 0.93 | TACR2 (0.51) | TACR2 | |
| SCHEMBL27538243 | 0.89 | TACR2 (0.45) | TACR2SIGMAR1ADRA1DADRA1AALDH1A1 | |
| SCHEMBL6891302 | 0.89 | TACR2 (0.45) | TACR2SIGMAR1ADRA1DADRA1AALDH1A1 | |
| SCHEMBL6890442 | 0.87 | ALDH1A1 (0.40) | TACR2CTSLALDH1A1SMN1; SMN2 | |
| SCHEMBL6890418 | 0.87 | ALDH1A1 (0.44) | SIGMAR1CTSLALDH1A1SMN1; SMN2 | |
| SCHEMBL6897691 | 0.87 | ALDH1A1 (0.44) | SIGMAR1CTSLALDH1A1SMN1; SMN2 | |
| SCHEMBL6891200 | 0.87 | CTSL (0.40) | CTSLALDH1A1SMN1; SMN2 | |
| SCHEMBL27541537 | 0.87 | CTSL (0.40) | CTSLALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20040071853-A1 | For improving rheological properties of a flour dough and the quality of bread, alimentary paste products, noodles and cakes | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2004-04-15 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | TACR2 94/4885SIGMAR1 26/4885ADRA1D 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.